Gujar S, Pol JG, Kim Y, Kroemer G
Oncoimmunology 9 (1) 1794424 [2020-07-16; online 2020-07-16]
The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8 + T cells for cancer immunotherapy strategies.